Biotron Limited (ASX:BIT)

Australia flag Australia · Delayed Price · Currency is AUD
0.0040
+0.0010 (33.33%)
Jan 30, 2026, 2:34 PM AEST
-75.00%
Market Cap7.23M
Revenue (ttm)1.81M +10.2%
Net Income-318.57K
EPS-0.00
Shares Out2.41B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,999,697
Average Volume5,403,460
Open0.0040
Previous Close0.0030
Day's Range0.0030 - 0.0040
52-Week Range0.0020 - 0.0160
Beta-0.93
RSI48.30
Earnings DateFeb 22, 2026

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 3
Stock Exchange Australian Securities Exchange
Ticker Symbol BIT
Full Company Profile

Financial Performance

In 2025, Biotron's revenue was 1.81 million, an increase of 10.24% compared to the previous year's 1.65 million. Losses were -318,572, -90.73% less than in 2024.

Financial Statements